Lisa Raedler, PhD, RPh


Medical Writer

Authored Items

Other Recent Key Presentations in Oncology

Uncategorized

Humanized Monoclonal Antibody Shows Promise in Combination Therapy in Chronic Lymphocytic Leukemia with Comorbidities Chemoimmunotherapy (CIT)—typically fludarabine, cyclophosphamide, and rituximab—is standard of care for young and physically-fit patients with chronic lymphocytic leukemia (CLL). There is no standard of care, however, for older and less fit patients with CLL. At the [ Read More ]

BRAF Inhibition: Halting Cancer Cell Growth

Uncategorized

Cancers develop when mutations in critical genes alter cells’ ability to proliferate, differentiate, and die. One of these critical genes is the BRAF gene. Mutations in BRAF result in overactive, or oncogenic, BRAF protein, which ultimately enhances cell proliferation and survival.1 Because BRAF mutations are present in more than half [ Read More ]

JAK Inhibition: Blocking Cytokine Signaling in Cancer Cells

Uncategorized

Cells in living organisms function and grow in response to cell-signaling cytokines, including various proteins, peptides, and glycoproteins. Given their central role in the body’s regulation of cell growth and immune responses, cytokines are highly appealing targets for therapeutic intervention in various diseases, including inflammatory conditions, bone disorders, metabolic diseases, [ Read More ]

BCL-2 Inhibition: Hastening Cancer Cell Death

Uncategorized

All treatments for cancer either remove or kill cancer cells. Whether it is surgery, radiation, chemotherapy, or biologic therapy, the goal is to eradicate cancer cells without destroying the patient’s healthy cells. Consider the example of microtubule inhibitors (MTIs)—paclitaxel, eribulin, ixabepilone, and others. All agents in this class affect cancer [ Read More ]

Introduction

Uncategorized

As evidenced by the 2013 annual meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), the pace at which scientific knowledge is influencing cancer drug development is astounding. Breakthroughs in our collective understanding of the underlying biology [ Read More ]

Highlights From the 6th International Symposium on Acute Promyelocytic Leukemia

September 2014, Vol 3, No 6 - Uncategorized

Recently, more than 200 scientists, researchers, and clinicians from around the globe gathered in Rome, Italy, for the 6th International Symposium on Acute Promyelocytic Leukemia (APL). Held every 4 years since 1997, this comprehensive congress reviewed recent scientific advances and clinical research in APL and related malignancies. Two internationally recognized [ Read More ]

Immuno-Oncology Takes Center Stage

June 2014, Part 2 - Uncategorized

More than 120 years after William Coley, MD, administered intratumoral injections of bacteria to patients with cancer with the goal of generating spontaneous remission,1 the number and complexity of immunomodulatory strategies for this patient population have grown exponentially. More than 250 abstracts that included the term “immunotherapy” or “immuno-oncology” were [ Read More ]

The Treatment of Relapsed Metastatic Melanoma Using a Novel Immunotherapy Combination:

An Interview with Mario Sznol, MD

June 2014, Part 2 - Interview with the Innovators

During the 2014 annual meeting of the American Society of Clinical Oncology (ASCO), Mario Sznol, MD, presented Abstract LBA9003—Survival, Response Duration, and Activity by BRAF Mutation Status of Nivolumab and Ipilimumab Concurrent Therapy in Advanced Melanoma—on behalf of his colleagues and fellow investigators. The presentation summarized objectives, methods, and long-term [ Read More ]

Sign me up!